Like in other industry verticals, healthcare firms are also supplementing their business acumen by linking the capability of artificial intelligence with human activities. AI can assist pharmaceutical companies to gain considerable insights into their business by reviewing and interpreting comprehensive datasets. More significantly, machine learning can solve problems that typically cause roadblocks for pharmaceutical developments, primarily the painstakingly long time frames for drug discovery and regulatory approvals. Albeit the uptake of AI in the pharma sector has been relatively slow, but lately, it appears to be on fast-track. Now several entities in the medical industry are keen to understand how this technology works, and what benefits or new challenges it can bring along.
AI can also play a pivotal role in reducing context-specific ‘noise’ from humungous data sets. It shortens the time to achieve actionable data insights and plays a vital role in garnering in-depth knowledge of medical data. Owing to such promising benefits, AI is expected to be a ubiquitous tenant of the medical industry in the near future.
Weekly Brief
Read Also
